Emmanuel During, MD
Neurology · New York
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Icahn School of Medicine at Mount Sinai · 2,809 clinicians in this group
Looking this up.
Hospitals listed: Mount Sinai Beth Israel. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. During’s office at (212) 241-9410 to ask if they take your plan before you enroll.
California Medical Board record
Licence A131016 · Delinquent
Licence status: Delinquent · since 2014 · expires 2022-06-30 · University of Paris Vii U.F.R. of Medicine Denis Diderot.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Mount Sinai Beth IsraelNew York, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Mount Sinai Health System, which runs 5 hospitalsPatients rate it 2 of 5 · 56% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Mount Sinai Beth Israel
Behind the star rating — Deaths: 3 better, 4 the same, 0 worse of 7 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.81 (0 to 1.77) · 1,485 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.97 (0.64 to 1.31) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 148.44 (90.91 to 205.97) · 39 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.3 · 120 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 99 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.4 · 476 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.3 · 627 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 7.7 · 314 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 3,702 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.33) · 9,236 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.04 to 0.4) · 9,516 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.58 (1.46 to 5.7) · 1,046 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.63 (0 to 3.34) · 94 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.16 (0.69 to 3.64) · 1,049 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.16 (3.07 to 21.25) · 131 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.37 (2.26 to 10.47) · 118 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.18 to 3.16) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.74) · 7,990 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.9 · 39 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.817 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.2 · 89 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.9 · 842 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 26.2 · 71 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 41.5 · 499 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 59.1 · 612 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 822 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.6 to 7.2) · 321 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 8.7 (6.5 to 11.5) · 321 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 22.3 · 285 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.8 to 16.5) · 539 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1) · 633 cases | No different | Jan 2024 – Dec 2024 |
What patients said (181 patients answered, 12% of those asked)
| Cleanliness | 3 |
| Nurse communication | 1 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 1 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 71% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 77% |
| Yes, staff "did" give patients information about help after discharge | 71% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 77% |
| Patients who gave a rating of "9" or "10" (high) | 61% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 76% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 56% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$46,334
Medicare paid this office $46,334 for 180 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 113 | $22,537 | $130 |
| New patient visit (60+ min) | 72 | $11,927 | $166 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 53 | $3,995 | $27 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 151 | $3,281 | $14 |
| New patient visit (45+ min) | 18 | $2,258 | $125 |
Procedures Medicare counted
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
180 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 9% · Women 40% · Also on Medicaid 12% · Health risk score 1.43. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 66% · Coronary heart disease 36% · Depression 29% · Diabetes 28% · Dementia 20% · Atrial fibrillation 19% · Chronic kidney disease 18% · Cancer 18% · Heart failure 16% · COPD 12% · Stroke 12%.
The office billed $184,959, Medicare allowed $61,072 and paid $46,334; for 678 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 180 | 678 | 75 | 1.43 | $184,959 | $46,334 |
| 2023 | 162 | 306 | 73 | 1.39 | $130,645 | $32,970 |
| 2022 | 207 | 332 | 73 | 1.31 | $185,261 | $32,729 |
| 2021 | 190 | 289 | 72 | 1.38 | $232,684 | $30,210 |
| 2020 | 269 | 465 | 72 | 1.35 | $256,761 | $38,201 |
| 2019 | 457 | 646 | 72 | 1.39 | $168,645 | $56,990 |
| 2018 | 361 | 542 | 70 | 1.40 | $121,525 | $48,711 |
| 2017 | 340 | 509 | 71 | 1.24 | $161,809 | $48,146 |
| 2016 | 155 | 185 | 70 | 1.29 | $62,401 | $18,965 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Long return visit (40+ min) | 74 | $14,203 | $135 |
| New patient visit (60+ min) | 50 | $9,011 | $180 |
| Sleep study in sleep lab (6 years or older) | 24 | $2,523 | $105 |
| New patient visit (45+ min) | 20 | $2,513 | $126 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 34 | $1,847 | $28 |
| Home sleep study test (hst) with type ii portable monitor, unattended; minimum of 7 channels: eeg, eog, emg, ecg/heart rate, airflow, respiratory effort and oxygen saturation | 19 | $1,109 | $58 |
2022: 10 services
| Long return visit (40+ min) | 66 | $9,798 | $122 |
| Long return visit (40+ min) | 30 | $5,147 | $129 |
| New patient visit (60+ min) | 22 | $3,676 | $167 |
| New patient visit (45+ min) | 23 | $2,884 | $125 |
| Sleep study in sleep lab (6 years or older) | 17 | $1,758 | $103 |
| Home sleep study test (hst) with type ii portable monitor, unattended; minimum of 7 channels: eeg, eog, emg, ecg/heart rate, airflow, respiratory effort and oxygen saturation | 30 | $1,721 | $57 |
| Sleep study in sleep lab (6 years or older) | 16 | $1,655 | $97 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 18 | $1,222 | $30 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 11 | $1,218 | $111 |
| Return visit (30+ min) | 12 | $1,014 | $78 |
2021: 6 services
| Long return visit (40+ min) | 57 | $9,872 | $119 |
| Long return visit (40+ min) | 42 | $9,023 | $127 |
| New patient visit (60+ min) | 20 | $2,727 | $136 |
| New patient visit (60+ min) | 12 | $2,103 | $175 |
| Sleep study in sleep lab (6 years or older) | 17 | $1,860 | $109 |
| Sleep study including heart rate, breathing, and sleep time | 18 | $645 | $36 |
2020: 12 services
| Long return visit (40+ min) | 51 | $7,828 | $100 |
| Long return visit (40+ min) | 27 | $3,924 | $96 |
| New patient visit (60+ min) | 25 | $3,905 | $156 |
| Extended patient service without direct patient contact, first hour | 32 | $3,729 | $104 |
| Sleep study in sleep lab (6 years or older) | 34 | $3,432 | $101 |
| Extended patient service without direct patient contact, first hour | 28 | $3,055 | $105 |
| Return visit (30+ min) | 45 | $2,836 | $62 |
| Short return visit (20+ min) | 49 | $2,070 | $41 |
| Return visit (30+ min) | 22 | $1,319 | $57 |
| New patient visit (60+ min) | 13 | $779 | $60 |
| New patient visit (15+ min) | 17 | $741 | $44 |
| Short return visit (20+ min) | 12 | $475 | $40 |
2019: 9 services
| Long return visit (40+ min) | 97 | $13,361 | $93 |
| New patient visit (60+ min) | 61 | $8,430 | $138 |
| Long return visit (40+ min) | 54 | $7,440 | $94 |
| New patient visit (60+ min) | 45 | $6,330 | $141 |
| Sleep study in sleep lab (6 years or older) | 47 | $4,962 | $106 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 42 | $4,695 | $112 |
| Return visit (30+ min) | 61 | $3,921 | $59 |
| Short return visit (20+ min) | 84 | $3,693 | $43 |
| Return visit (30+ min) | 37 | $2,679 | $64 |
2018: 9 services
| Long return visit (40+ min) | 127 | $15,467 | $87 |
| New patient visit (60+ min) | 97 | $12,779 | $132 |
| Return visit (30+ min) | 103 | $7,961 | $66 |
| Sleep study in sleep lab (6 years or older) | 32 | $3,486 | $109 |
| Long return visit (40+ min) | 22 | $2,494 | $100 |
| New patient visit (60+ min) | 13 | $1,863 | $143 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 15 | $1,585 | $106 |
| Short return visit (20+ min) | 26 | $1,051 | $40 |
| Sleep study including heart rate, breathing, airflow, and effort | 12 | $660 | $55 |
2017: 6 services
| Long return visit (40+ min) | 133 | $16,793 | $91 |
| New patient visit (60+ min) | 126 | $16,670 | $132 |
| Return visit (30+ min) | 108 | $8,288 | $65 |
| Sleep study in sleep lab (6 years or older) | 23 | $2,405 | $105 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 19 | $2,115 | $111 |
| Sleep study including heart rate, breathing, airflow, and effort | 13 | $662 | $51 |
2016: 3 services
| New patient visit (60+ min) | 51 | $7,393 | $145 |
| Long return visit (40+ min) | 55 | $5,911 | $99 |
| Return visit (30+ min) | 59 | $4,275 | $70 |
Drugs they prescribed that Part D paid
$57,309
Pharmacies billed $57,309 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (14 of 365) in 2024. A higher opioid share than 9 in 10 peers; the typical neurology clinician is at 0%.
270 generic and 95 brand-name prescriptions · $57,309 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Belsomra | 50 | $21,352 | $427 |
| Neupro | 17 | $14,435 | $849 |
| Dayvigo | 20 | $6,370 | $318 |
| Rivastigmine | 27 | $3,797 | $141 |
| Gabapentin | 44 | $604 | $14 |
See all 10 drugs
| Belsomra | 50 | $21,352 | $427 |
| Neupro | 17 | $14,435 | $849 |
| Dayvigo | 20 | $6,370 | $318 |
| Rivastigmine | 27 | $3,797 | $141 |
| Gabapentin | 44 | $604 | $14 |
| Pregabalin | 19 | $366 | $19 |
| Trazodone | 48 | $221 | $5 |
| Pramipexole Dihydrochloride | 11 | $79 | $7 |
| Clonazepam | 22 | $62 | $3 |
| Zolpidem | 14 | $57 | $4 |
Year by year
| 2024 | 365 | 78 | 4% (14) | 26% | $57,309 |
| 2023 | 198 | 53 | None | 18% | $86,027 |
| 2022 | 358 | 74 | 12% (41) | 14% | $48,266 |
| 2021 | 664 | 90 | 16% (109) | 17% | $95,593 |
| 2020 | 594 | 96 | 16% (93) | 21% | $316,725 |
| 2019 | 663 | 111 | 13% (88) | 25% | $267,797 |
| 2018 | 514 | 127 | 16% (82) | 19% | $129,011 |
| 2017 | 273 | 93 | 10% (28) | 11% | $23,384 |
| 2016 | 64 | 28 | 34% (22) | 20% | $7,580 |
| 2015 | 83 | 15 | 0% (0) | 31% | $11,324 |
| 2014 | 58 | 12 | 0% (0) | 36% | $6,531 |
| 2013 | 17 | None | 0% (0) | None | $2,888 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Belsomra | 15 | $6,609 | $441 |
| Rivastigmine | 18 | $4,685 | $260 |
| Gabapentin | 49 | $1,157 | $24 |
| Zolpidem | 17 | $259 | $15 |
2022: 11 drugs
| Myrbetriq | 24 | $11,060 | $461 |
| Neupro | 13 | $10,630 | $818 |
| Carbidopa-Levodopa | 25 | $1,308 | $52 |
| Carbidopa-Levodopa Er | 12 | $1,174 | $98 |
| Pregabalin | 16 | $861 | $54 |
| Gabapentin | 74 | $801 | $11 |
| Bupropion Xl | 12 | $430 | $36 |
| Clonazepam | 28 | $330 | $12 |
| Methadone | 14 | $239 | $17 |
| Escitalopram | 11 | $173 | $16 |
| Tramadol | 16 | $58 | $4 |
2021: 21 drugs
| Neupro | 26 | $19,456 | $748 |
| Horizant | 20 | $18,441 | $922 |
| Rivastigmine | 31 | $12,333 | $398 |
| Myrbetriq | 29 | $12,209 | $421 |
| Belsomra | 14 | $5,445 | $389 |
| Pregabalin | 35 | $4,635 | $132 |
| Carbidopa-Levodopa Er | 31 | $2,277 | $73 |
| Carbidopa-Levodopa | 42 | $2,139 | $51 |
| Gabapentin | 91 | $2,036 | $22 |
| Ipratropium | 13 | $744 | $57 |
| Pramipexole Dihydrochloride | 28 | $659 | $24 |
| Methadone | 40 | $619 | $15 |
| Rivastigmine | 12 | $612 | $51 |
| Clonazepam | 40 | $605 | $15 |
| Modafinil | 11 | $491 | $45 |
| Tramadol | 20 | $452 | $23 |
| Oxycodone | 41 | $394 | $10 |
| Duloxetine | 13 | $256 | $20 |
| Escitalopram | 28 | $206 | $7 |
| Donepezil | 22 | $172 | $8 |
| Trazodone | 15 | $52 | $3 |
2020: 17 drugs
| Gammagard Liquid | Immune globulin | 12 | $223,885 | $18,657 |
| Rivastigmine | None | 37 | $14,261 | $385 |
| Horizant | None | 15 | $11,886 | $792 |
| Myrbetriq | None | 22 | $10,154 | $462 |
| Belsomra | None | 12 | $4,509 | $376 |
| Carbidopa-Levodopa Er | None | 26 | $4,484 | $172 |
| Pregabalin | None | 34 | $3,604 | $106 |
| Carbidopa-Levodopa | None | 42 | $1,905 | $45 |
| Gabapentin | None | 59 | $918 | $16 |
| Clonazepam | None | 39 | $552 | $14 |
| Ipratropium | None | 12 | $542 | $45 |
| Methadone | None | 29 | $400 | $14 |
| Oxycodone | None | 45 | $386 | $9 |
| Nortriptyline | None | 16 | $375 | $23 |
| Trazodone | None | 20 | $164 | $8 |
| Donepezil | None | 25 | $160 | $6 |
| Tramadol | None | 16 | $65 | $4 |
2019: 19 drugs
| Gammagard Liquid | Immune globulin | 17 | $189,488 | $11,146 |
| Rivastigmine | None | 42 | $13,038 | $310 |
| Horizant | None | 16 | $12,958 | $810 |
| Myrbetriq | None | 19 | $7,432 | $391 |
| Movantik | None | 12 | $4,304 | $359 |
| Carbidopa-Levodopa Er | None | 27 | $3,797 | $141 |
| Carbidopa-Levodopa | None | 47 | $1,881 | $40 |
| Gabapentin | None | 91 | $1,523 | $17 |
| Armodafinil | None | 14 | $1,413 | $101 |
| Methadone | None | 51 | $687 | $13 |
| Clonazepam | None | 43 | $543 | $13 |
| Bupropion Xl | None | 23 | $442 | $19 |
| Nortriptyline | None | 27 | $351 | $13 |
| Pramipexole Dihydrochloride | None | 16 | $344 | $21 |
| Oxycodone | None | 20 | $282 | $14 |
| Ropinirole | None | 14 | $223 | $16 |
| Venlafaxine Hcl Er | None | 11 | $150 | $14 |
| Trazodone | None | 11 | $145 | $13 |
| Tramadol | None | 17 | $35 | $2 |
2018: 10 drugs
| Horizant | 22 | $12,548 | $570 |
| Carbidopa-Levodopa | 51 | $1,773 | $35 |
| Gabapentin | 115 | $1,605 | $14 |
| Clonazepam | 40 | $716 | $18 |
| Pramipexole Dihydrochloride | 25 | $582 | $23 |
| Methadone | 43 | $573 | $13 |
| Oxycodone | 14 | $232 | $17 |
| Trazodone | 31 | $230 | $7 |
| Donepezil | 14 | $196 | $14 |
| Tramadol | 17 | $26 | $2 |
2017: 5 drugs
| Carbidopa-Levodopa | 28 | $668 | $24 |
| Gabapentin | 59 | $629 | $11 |
| Pramipexole Dihydrochloride | 20 | $496 | $25 |
| Methadone | 21 | $314 | $15 |
| Trazodone | 28 | $158 | $6 |
2015: 2 drugs
| Vimpat | 13 | $6,218 | $478 |
| Donepezil | 12 | $135 | $11 |
2014: 1 drug
| Donepezil | 11 | $159 | $14 |
Money from drug and device companies
$135 in 2025
| 2025 | 1 | 1 | None | $135 |
| 2024 | 1 | 1 | $1,250 | $1,250 |
| 2019 | 1 | 1 | None | $41 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Jazz Pharmaceuticals | Xywav | $135 | 1 payment
|
See the published payment
| Jazz Pharmaceuticals | Meals · 2025-06-11 | Xywav | $135 |
See earlier years (2024, 2019)
2024: $1,250
| Genzyme | Dupixent | $1,250 | 1 payment
|
2019: $41
| Jazz Pharmaceuticals | Xyrem | $41 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| JAZZ PHARMACEUTICALS INC. · Sodium Oxybate in Refractory Rem Sleep Behavior Disorder: A Randomized Controlled Study · 2019 | Their institution | $405,183 |
| JAZZ PHARMACEUTICALS INC. · Sodium Oxybate in Refractory Rem Sleep Behaviour Disorder: A Randomised Controlled Study · 2020 | Their institution | $75,498 |
| Regeneron Pharmaceuticals, Inc. · Dupixent Clinical Development Program · 2022 | This clinician | $9,630 |
| GENZYME CORPORATION · A Randomized Double-Blind, Placebo-Controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate To Severe Atopic Dermatitis (Ad) · 2022 | This clinician | $2,500 |
| GENZYME CORPORATION · A Randomized Double-Blind, Placebo-Controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate To Severe Atopic Dermatitis (Ad) · 2023 | This clinician | $1,500 |
| Regeneron Pharmaceuticals, Inc. · Dupixent Clinical Development Program · 2023 | This clinician | $1,344 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Study To Assess the Frequency and Characteristics of Wake and Sleep State Transitions Over Multiple Nights in Subjects With Narcolepsy Type 1 Compared With Healthy Subjects Using A Portable Electroencephalogram Device · 2021 | This clinician | $1,325 |
| Regeneron Pharmaceuticals, Inc. · Dupixent Clinical Development Program · 2021 | This clinician | $1,027 |
| GENZYME CORPORATION · A Randomized Double-Blind, Placebo-Controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate To Severe Atopic Dermatitis (Ad) · 2021 | This clinician | $750 |
Professional record
- NPI
- 1104110212
- Licence
- AZ R72835, CA A131016, NY 316629California A131016: Delinquent · expires 2022-06-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Neurology (2084N0400X); Internal medicine (207R00000X); Federal specialty code 207RS0012X (207RS0012X); Psychiatry (2084P0800X)
- Mailing address
- 10 Union Sq E Frnt 5, New York, NY, 10003
- NPI first listed
- 2011-06-06
- NPI last updated
- 2022-07-13
- NPI record certified
- 2022-06-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1 Gustave L Levy Pl, New York, NY, 10029 · 5 E 98th St, New York, NY, 10029 · 300 Pasteur Dr, Stanford, CA, 94305